Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof

• US 7,267,829 B2
• Filed: 04/23/2004
• Issued: 09/11/2007
• Est. Priority Date: 07/07/1998
• Status: Expired due to Term

• Current Assignee: Transdermal Delivery Solutions Corporation
• Original Assignee: Transdermal Biotechnology, Inc.
• Inventors: Kirby, Kenneth B, Pettersson, Berno
• Primary Examiner(s): GHALI, ISIS A D
• Application Number:
  US10/831,416
• Publication Number:
  US 20040202709A1
• Time in Patent Office: 1,236 Days
• Field of Search: None
• US Class Current: 424/449
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 36/232 Angelica
• CPC Class Codes: A61K 36/324 Boswellia, e.g. frankincense
• CPC Class Codes: A61K 36/53 Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• CPC Class Codes: A61K 36/74 Rubiaceae (Madder family)
• CPC Class Codes: A61K 36/752 Citrus, e.g. lime, orange or lemon
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders

Abstract

A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.

Claims

1. A liquid transdermal delivery system (TDS) for treatment of a living body by rapidly delivering an effective dose of at least 0.25 mg/cm2/day of at least one active agent across the skin by application of said TDS to an area of the skin, said TDS comprising, in combination, said at least one active agent and a solvent system in which the active agent is at least substantially soluble, said solvent system including at least one solvent modifying compound to facilitate transdermal delivery of the active agent and to increase solubility of said active agent in said solvent system;

and at least one active agent modifying compound forming a non-covalently bonded complex with the active agent, said at least one active agent having a molecular weight in excess of 300 Daltons, wherein said solvent system is selected so as to exhibit van der Waals forces subsequent to inclusion of said active agent which closely approximate those exhibited by said solvent system alone;

said act of solvent system selection including determining the van der Waals forces of the active agent, selecting a solvent system such that the weighted average of van der Waals forces of components of said solvent system closely approximate the van der Waals forces of said active agent, and such that upon combination of said solvent system and said active agent to form said TDS, the van der Waals forces of said TDS closely approximate the van der Waals forces of said active agent and said solvent system prior to formation of said TDS;

wherein said transdermal delivery system includes

(a) a medically effective active ingredient, and

(b) a carrier composition comprising;

(i) at least one non-agueous non-toxic solvent selected from the group consisting of lower aliphatic mono-hydroxy and poly-hydroxy compounds;

(ii) limonene, lemon oil or mixture of limonene and lemon oil;

(iii) methylsulfonylmethane;

(iv) a skin stabilizer which comprises at least one compound selected from the group consisting of an aliphatic carboxylic acid having from 8 to 32 carbon atoms, an ester of said aliphatic carboxylic acid with an aliphatic alcohol having from 1 to 20 carbon atoms, wherein said ester has a total of from 9 to 36 carbon atoms; and

Vitamin D3; and

(v) a solute modifier which comprises a compound selected from the group consisting of 3,3′

-thiodipropionic acid, Uncaris Tormentosa, an oxindole alkaloid, a polyphenolic flavonoid, a sugar adduct of a gluconuide, isoflavones, phosphatidyl serine, phosphatidyl choline, Vitamin D3 and Vitamin K1.

2. A TDS of claim 1 wherein said molecular weight of said active agent is from about 340 Daltons to about 22,000 Daltons.

3. A TDS of claim 1 wherein said effective dose is from about 0.25 mg/cm2/day to about 1 mg/cm2/day.

4. A TDS of claim 3 wherein said molecular weight of said active agent is from about 340 Daltons to about 22,000 Daltons.

5. A TDS of claim 1 wherein said TDS is formed as a unit dose, said unit dose being approximately 1 cc, said unit dose comprising from about 0.25 mg to about 1 mg of said medicament.

6. A TDS of claim 5 wherein said unit dose is a liquid.

7. The transdermal delivery system of claim 1, wherein said van der Waals forces of said TDS are within about 15% of the van der Waals forces of said solvent system or said active agent, individually, prior to forming said TDS.

8. The transdermal delivery system of claim 1, wherein said van der Waals forces of said TDS are within about 10% of the van der Waals forces of said solvent system or said active agent, individually, prior to forming said TDS.

9. The transdermal delivery system of claim 1, wherein said van der Waals forces of said TDS are within about 5% of the van der Waals forces of said solvent system or said active agent, individually, prior to forming said TDS.

10. The transdermal delivery system of claim 1, further including:

adenosine triphosphate (ATP) or a compound which induces generation of cyclic adenosine 3′

5′

monophosphate cAMP in situ or cyclic quanosina monophosphate (cGMP) in situ, wherein the compound which induces generation of cAMP or cGMP is pure forskolin or 40% FORSKOLIN.

11. The transdermal delivery system of claim 10 wherein said carrier composition comprises: